24 results about "Cancer cachexia" patented technology

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

The invention belongs to the technical field of biological medicines, and particularly relates to application of miR-206-3p in regulation and control of skeletal muscle atrophy, and the change condition of the miR-206-3p level is measured by constructing an in-vitro cancer cachexia myotubular atrophy model; it is verified that in-vitro addition of miR-206-3p mimics relieves in-vitro myotube atrophy induced by a cancer conditioned culture medium, inhibits expression of a myotube marker gene and inhibits proteolysis and metabolism pathways and cell apoptosis of myotubes, so that myotube atrophy induced by cancer cachexia is inhibited. The invention opens up a new thought for the research of cachexia pathogenesis, and also provides a potential new target for the research and development of cachexia treatment and / or cachexia prevention drugs.

The present invention relates to a composition for ameliorating or treating cachexia containing calcium lactate as an active ingredient, and a method for treating cancer cachexia in a subject, the method comprising a step of administering calcium lactate or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The calcium lactate of the present invention acts as a Hif-1α inhibitor and exhibits an effect of suppressing body mass loss due to cancer, so that it can be used as a candidate substance for solving the problem of cancer cachexia and suggests a synergistic effect between a medical nutritional product focused on anorexia and malnutrition and a Hif-1α inhibitor.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of various conditions, including but not limited to congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by elevated leptin signaling.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present invention relates to: a GFRAL-specific antisense oligomer that targets the GDNF family alpha-like receptor (GFRAL) gene; and a pharmaceutical composition for preventing or treating obesity, diabetes, anorexia or cachexia, the pharmaceutical composition comprising the antisense oligomer. It was found that the antisense oligomer according to the present invention effectively inhibits the expression of GFRAL in vivo and exhibits an improved effect in a cancer cachexia animal model. Therefore, by inhibiting the expression of the GFRAL, the antisense oligomer has a wide application prospect as an agent for treating obesity or cachexia.

The present invention relates to monoclonal anti-human-(IDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

The present invention relates to a GDNF family receptor alpha like (GFRAL)-specific antisense oligomer targeting the GFRAL gene and a pharmaceutical composition containing the same for preventing or treating obesity, diabetes, anorexia, or cachexia. It has been confirmed that the antisense oligomer according to the present invention effectively suppresses GFRAL expression in vivo and shows ameliorative effects in an animal model of cancer cachexia. Therefore, it is expected to be highly applicable as a therapeutic agent for obesity or cachexia through the suppression of GFRAL expression.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The application relates to application of a compound in the biological medical field, in particular to application of a benzamide compound in preparation of a drug for preventing and / or treating cancer cachexia. The application of the compound shown in formula I or a pharmaceutically acceptable salt thereof in preparation of a drug for preventing and / or treating cancer cachexia. The compound involved in the application has the effect of significantly improving, reducing and alleviating cancer cachexia, improving the weight of animal body, bone muscle and fat, and has a good application and development prospect.

Disclosed herein is a method for promoting insulin sensitivity in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an monocarboxylate transporter 1 (MCT1) inhibitor. For example, the subject can have or be at risk of developing a metabolic disorder characterized by high blood glucose and low insulin levels, e.g., type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and atherosclerosis. The subject can also have been diagnosed with cancer cachexia or with a cancer, such as a solid tumor or lymphoma.

A digital apparatus for treating cancer cachexia in a subject are provided. A processor of the digital apparatus provides, by the digital apparatus to the subject, one or more first modules selected from the group consisting of external activity modules and an internal activity module, each of the one or more first modules comprising one or more first instructions for the subject to follow. The one or more first instructions are selected from a plurality of external activity instructions of the external activity modules and a plurality of internal activity instructions of the internal activity module. The processor provides the one or more first module for a predetermined period having a plurality of sections, each of the plurality of sections comprises different combinations of the plurality of external activity instructions of the external activity module.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The present invention relates to a novel use of a CXCL5 inhibitor and a novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor. The novel use of a CXCL5 inhibitor and the novel antibody or antigen-binding fragment thereof usable as a CXCL5 inhibitor of the present invention enable the treatment or prevention of cancer cachexia or muscle disease, enable cancer cachexia or muscle disease to be diagnosed with high efficiency, and enable a drug for the treatment or prevention of cancer cachexia or muscle disease to be screened with high efficiency.

The application relates to the technical field of medical systems, and particularly discloses a construction method of a cancer cachexia prognosis composite index CCAR based on a combination of creatinine and CAR, which comprises the following steps: S1, obtaining serum biomarker data of a cancer cachexia patient, including creatinine, C-reactive protein and albumin; S2, calculating a C-reactive protein to albumin ratio CAR=CRP / Albumin; S3, taking CAR and Cr as input features, and constructing a nonlinear composite index CCAR through a random forest machine learning model; and S4, developing a network calculator system; the CCAR index constructed by the application can comprehensively reflect the inflammatory burden, metabolic state and immune level of a cancer cachexia patient, can provide more accurate survival prognosis prediction compared with traditional indexes, and the parameters, such as creatinine, C-reactive protein to albumin ratio, contained in the CCAR index are all common blood examination items in clinical practice, so that the CCAR index is convenient to obtain and can be widely applied in clinical practice.

The present invention relates to a composition for ameliorating or treating cachexia containing calcium lactate as an active ingredient, and a method for treating cancer cachexia in a subject, the method comprising a step of administering calcium lactate or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The calcium lactate of the present invention acts as a Hif-1α inhibitor and exhibits an effect of suppressing body mass loss due to cancer, so that it can be used as a candidate substance for solving the problem of cancer cachexia and suggests a synergistic effect between a medical nutritional product focused on anorexia and malnutrition and a Hif-1α inhibitor.

The invention is directed to methods of treating cancer cachexia or cancer by administering to the patient a GDF15 antibody ponsegromab, and especially while the patient is receiving a systemic chemotherapy.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The present invention relates to a composition for ameliorating and treating a muscle disease and cachexia, which includes diflunisal. The diflunisal has an effect of promoting the differentiation and proliferation of myoblast cells, and also has an effect of ameliorating and treating cachexia caused by muscle diseases or chronic diseases such as cancer through effects such as increasing muscle mass, recovering muscle strength, and the like.

Provided are: a prophylactic or ameliorating agent for cachexia, which contains a phospholipid and / or lysophospholipid as an active ingredient; and a method for screening a substance for ameliorating cachexia. This prophylactic or ameliorating agent for cachexia is effective not only against cancer cachexia but also against cachexia caused by diseases other than cancer, and is capable of suppressing reduction in skeletal muscle content, suppressing lipoatrophy, and suppressing the expression of inflammatory cytokines.

The invention discloses a 1H-pyrazol (role) [3, 4-b] pyridine compound, a pharmaceutical composition and application of the 1H-pyrazol (role) [3, 4-b] pyridine compound, and belongs to the field of chemical medicines. The invention provides 1H-pyrazole (role)-[3, 4-b] pyridine derivatives with a structure as shown in a general formula (I) or pharmaceutically acceptable salts thereof, and the compounds have excellent ActRIIB inhibition effects and can be used as drugs for treating or preventing ActRIIB-mediated diseases (including cancer cachexia).

The invention relates to an application of an indoleamine 2, 3-dioxygenase 1 inhibitor in preparation of a medicine for treating cancer cachexia. The indoleamine 2, 3-dioxygenase 1 is determined as a core therapeutic target of cancer cachexia for the first time, and it is proved that palmatine hydrochloride shows an exact therapeutic effect in cell and animal models through a multi-channel synergistic mechanism of metabolic reprogramming, protein degradation inhibition, anabolism signal recovery and muscle regeneration promotion. And sufficient experimental basis and theoretical support are provided for clinical transformation.